MCL1 and prostate carcinoma: Indeed, we reported that downregulation of MCL-1 by RNAi or CRISPR can dramatically enhance the apoptotic response to navitoclax in prostate cancer cells in vitro and in vivo, with complete responses in established prostate cancer xenografts15.